243 related articles for article (PubMed ID: 11464874)
1. Observation of untreated patients with neuroblastoma detected by mass screening: a "wait and see" pilot study.
Yoneda A; Oue T; Imura K; Inoue M; Yagi K; Kawa K; Nishikawa M; Morimoto S; Nakayama M
Med Pediatr Oncol; 2001 Jan; 36(1):160-2. PubMed ID: 11464874
[TBL] [Abstract][Full Text] [Related]
2. Profile of neuroblastoma detected by mass screening, resected after observation without treatment: results of the Wait and See pilot study.
Oue T; Inoue M; Yoneda A; Kubota A; Okuyama H; Kawahara H; Nishikawa M; Nakayama M; Kawa K
J Pediatr Surg; 2005 Feb; 40(2):359-63. PubMed ID: 15750929
[TBL] [Abstract][Full Text] [Related]
3. Outcome of infants with neuroblastoma detected by mass screening and surgically treated in Shiga Prefecture, Japan: what is the role of surgery?
Hase T; Ohta S; Tani T; Mizukuro T; Mekata E; Naitoh H; Shimadera S; Fujino S; Taga T
Pediatr Surg Int; 2002 Sep; 18(5-6):289-94. PubMed ID: 12415341
[TBL] [Abstract][Full Text] [Related]
4. Neuroblastoma detected by mass screening: the Tumor Board's role in its treatment.
Okazaki T; Kohno S; Mimaya J; Hasegawa S; Urushihara N; Yoshida A; Kawano S; Kusafuka J; Horikoshi Y; Takashima Y; Aoki K; Hamazaki M
Pediatr Surg Int; 2004 Jan; 20(1):27-32. PubMed ID: 14689211
[TBL] [Abstract][Full Text] [Related]
5. Natural course of neuroblastoma detected by mass screening: s 5-year prospective study at a single institution.
Nishihira H; Toyoda Y; Tanaka Y; Ijiri R; Aida N; Takeuchi M; Ohnuma K; Kigasawa H; Kato K; Nishi T
J Clin Oncol; 2000 Aug; 18(16):3012-7. PubMed ID: 10944135
[TBL] [Abstract][Full Text] [Related]
6. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
[TBL] [Abstract][Full Text] [Related]
7. A prospective study of a long-term follow-up of an observation program for neuroblastoma detected by mass screening.
Tanaka M; Kigasawa H; Kato K; Ijiri R; Nishihira H; Aida N; Ohama Y; Tanaka Y
Pediatr Blood Cancer; 2010 Apr; 54(4):573-8. PubMed ID: 20049932
[TBL] [Abstract][Full Text] [Related]
8. A trial to discriminate spontaneous regression from non-regression cases during mass screening for neuroblastoma.
Nishi M; Miyake H; Takeda T; Yonemori H; Hanai J; Kikuchi Y; Takasugi N
Jpn J Clin Oncol; 1994 Oct; 24(5):247-51. PubMed ID: 7967103
[TBL] [Abstract][Full Text] [Related]
9. Results for 79 patients with neuroblastoma detected through mass screening at 6 months of age in a single institute.
Nishio N; Mimaya J; Nara T; Takashima Y; Horikoshi Y; Urushihara N; Hasegawa S; Aoki K; Hamasaki M
Pediatr Int; 2006 Dec; 48(6):531-5. PubMed ID: 17168969
[TBL] [Abstract][Full Text] [Related]
10. Role of ultrasound in managing neuroblastoma detected by mass screening: a proposed ultrasonographic grading for children with neuroblastoma.
Hirata T; Tatara H; Zaizen Y; Suita S; Matsuzaki A; Ueda K
J Clin Ultrasound; 1995 Jun; 23(5):305-13. PubMed ID: 7642769
[TBL] [Abstract][Full Text] [Related]
11. Retroperitoneal ganglioneuroblastoma resected 8 years after mass screening: a case report.
Nakaoka T; Uemura S; Nakagawa Y; Yano T; Oda M
J Pediatr Surg; 2007 Nov; 42(11):E29-32. PubMed ID: 18022424
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up results of the observation program for neuroblastoma detected at 6-month mass screening.
Arakawa A; Oguma E; Aihara T; Kishimoto H; Kikuchi A; Hanada R; Koh K
J Pediatr; 2014 Oct; 165(4):855-7.e1. PubMed ID: 25091258
[TBL] [Abstract][Full Text] [Related]
13. Mass screening of neuroblastoma in Sapporo City, Japan.
Nishi M; Miyake H; Takeda T; Kikuchi Y; Hanai J; Yonemori H; Takasugi N
Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):327-31. PubMed ID: 1456398
[TBL] [Abstract][Full Text] [Related]
14. Connatal localized neuroblastoma. The case to delay treatment.
Kerbl R; Urban CE; Lackner H; Höfler G; Ambros IM; Ratschek M; Ambros PF
Cancer; 1996 Apr; 77(7):1395-401. PubMed ID: 8608521
[TBL] [Abstract][Full Text] [Related]
15. Stephen L. Gans overseas lecture. Mass screening for neuroblastoma in Japan: lessons learned and future directions.
Suita S
J Pediatr Surg; 2002 Jul; 37(7):949-54. PubMed ID: 12077747
[TBL] [Abstract][Full Text] [Related]
16. [Present status of neuroblastoma mass screening in Japan. Neuroblastoma-Committee of the Japanese Childhood Cancer Society].
Sawada T; Nagahara N; Ohi R; Yamamoto K; Okabe I; Hanawa Y; Hashizume K; Matsui I; Ohkawa H; Tunoda A
Gan To Kagaku Ryoho; 1990 Dec; 17(12):2319-26. PubMed ID: 2260868
[TBL] [Abstract][Full Text] [Related]
17. Biological aspects of neuroblastomas identified by mass screening in Quebec.
Brodeur GM; Look AT; Shimada H; Hamilton VM; Maris JM; Hann HW; Leclerc JM; Bernstein M; Brisson LC; Brossard J; Lemieux B; Tuchman M; Woods WG
Med Pediatr Oncol; 2001 Jan; 36(1):157-9. PubMed ID: 11464873
[TBL] [Abstract][Full Text] [Related]
18. Effects of mass screening for neuroblastoma and the presumptive natural history of this tumor.
Takeda T; Shimada M; Iizuka S; Takasugi N
Prog Clin Biol Res; 1994; 385():383-8. PubMed ID: 7972235
[TBL] [Abstract][Full Text] [Related]
19. Neuroblastoma: epidemiology and pattern of regression. Problems in interpreting results of mass screening.
Carlsen NL
Am J Pediatr Hematol Oncol; 1992 May; 14(2):103-10. PubMed ID: 1530115
[TBL] [Abstract][Full Text] [Related]
20. Past and future of neuroblastoma screening in Japan.
Sawada T
Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):320-6. PubMed ID: 1456397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
